Clinical trials: Atopic Disorders
Atopic Dermatitis
Dupilumab-pediatric Skin Barrier Function and Lipidomics Study in Patients With Atopic Dermatitis in China
This is a 32-week, open-label, exploratory study with a 4-week screening period, 16-week treatment phase designed to investigate dupilumab's effect on skin barrier function as measured by TEWL before and after STS in…
- Trial name
- PELISTAD CN (NCT05680298)
- Testing
- Dupilumab
- Where
- China
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Sanofi
Dermatitis, Atopic
Study to Evaluate Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years And Older With Moderate to Severe Atopic Dermatitis
B7451012 is a Phase 3 study to evaluate PF-04965842 in patients aged 12 years and older with a minimum body weight of 40 kg who have moderate to severe atopic dermatitis.
- Trial name
- JADE Mono-1 (NCT03349060)
- Testing
- PF-04965842 100 mg, PF-04965842 200 mg
- Where
- 88 sites in United States, Australia and 6 more
- Volunteers
- 387 people
- Sponsor
- Pfizer
Atopic Dermatitis
A Study to Learn About the Study Medicine (CIBINQO) in People With Atopic Dermatitis.
The purpose of this study is to learn about the safety and effectiveness (how well the study treatment works) of the study medicine (CIBINQO) for the potential treatment of atopic dermatitis in people under Japanese medical…
- Trial name
- NCT05387980
- Testing
- CIBINQO
- Where
- Japan
- Volunteers
- 1,128 people
- Sponsor
- Pfizer
Atopic Dermatitis
Comparison of LimpiAD Cream 2.5% Plus Versus Its Vehicle and and a Basic Emollient in Patients With Atopic Dermatitis
The purpose of this clinical trial is to assess the efficacy and tolerability of LimpiAD, a medical device in the formulation of a 2.5% Plus cream, versus the Vehicle of LimpiAD 2,5% Plus cream, and versus a basic emollient in…
- Trial name
- NCT05984420
- Testing
- LimpiAD 2,5% plus cream, Vehicle, Emollient
- Where
- 5 sites in Italy
- Volunteers
- 200 people
- Sponsor
- Aileens Pharma SRL
Atopic Dermatitis
Study to Assess the Safety and Efficacy of Lebrikizumab (LY3650150) in Adolescent Participants With Moderate-to-Severe Atopic Dermatitis
This is an open-label, single arm study of 52 weeks duration. The study will assess the safety and efficacy of lebrikizumab in adolescent participants (≥12 to <18 years weighing ≥40 kilograms) with moderate-to-severe atopic…
- Trial name
- ADore (NCT04250350)
- Testing
- Lebrikizumab
- Where
- 70 sites in United States, Australia and 2 more
- Volunteers
- 206 people
- Sponsor
- Eli Lilly and Company
Dermatitis, Atopic
Treatment and Control of Atopic Dermatitis With 0.03% Tacrolimus Ointment
A long-term 0.03% tacrolimus ointment based regimen comprising of up to 6 weeks of initial twice daily treatment and subsequent twice weekly prophylactic application can effectively treat active lesions of atopic dermatitis, and…
- Trial name
- NCT00480896
- Testing
- tacrolimus ointment
- Where
- 22 sites in Belgium, Czechia and 9 more
- Volunteers
- 250 people
- Sponsor
- Astellas Pharma Inc
Food Allergy
Atopy Patch Test in Children With Food Allergy-related Gastrointestinal Symptoms
Positive reactions in Atopy patch test in children with food allergy-related gastrointestinal symptoms
- Trial name
- APT (NCT01164293)
- Testing
- Atopy patch test with food allergen
- Where
- Thailand
- Volunteers
- 40 people
- Sponsor
- Mahidol University
Asthma, Atopic Dermatitis
Polish Mother and Child Cohort Study (REPRO_PL) - Follow up of the Children.
The Polish Mother and Child Cohort is multicentre prospective study on different exposures. Prospective cohort study design enables identification of exposures that may influence pregnancy outcome and chil-dren's health…
- Conditions
- Asthma, Atopic Dermatitis, Food Allergy, Wheezing
- Trial name
- REPRO_PL (NCT01861548)
- Where
- 2 sites in Poland
- Volunteers
- 479 people, healthy volunteers welcome
- Sponsor
- Medical University of Lodz
Dermatitis, Atopic, Dermatitis
Abrocitinib Taiwan Treatment Pattern and Real World Study in ATopiC Dermatitis (ATTRACT Registry)
This study is to describe the real-world treatment patterns and clinical outcomes in moderate-to-severe AD patients receiving abrocitinib over a 12-month observation period, and to describe patient demographic and baseline…
- Conditions
- Dermatitis, Atopic, Dermatitis, Eczema, Skin Diseases
- Trial name
- ATTRACT (NCT06353087)
- Where
- 8 sites in Taiwan
- Volunteers
- 41 people
- Sponsor
- Pfizer
Dermatitis, Atopic
Safety, Pharmacokinetics and Efficacy of Dupilumab in Patients ≥6 Months to <6 Years With Moderate-to-Severe Atopic Dermatitis (Liberty AD PRESCHOOL)
This study is a 2-part (parts A and B) phase 2/3 study to evaluate the safety, pharmacokinetics (PK) and efficacy of dupilumab in participants 6 months to less than 6 years of age with moderate-to-severe atopic dermatitis (AD).
- Trial name
- Liberty AD (NCT03346434)
- Testing
- Dupilumab
- Where
- 48 sites in United States, Germany and 2 more
- Volunteers
- 202 people
- Sponsor
- Regeneron Pharmaceuticals
Atopic Dermatitis, Psoriasis
Meditation in Inflammatory Dermatosis
Psoriasis and atopic dermatitis are multifactorial inflammatory dermatoses, with a very high prevalence, reaching more than 120 million patients in the world.
- Conditions
- Atopic Dermatitis, Psoriasis, Pruritus
- Trial name
- MediDermIn (NCT05500794)
- Testing
- MBSR (Mindfulness-Based Stress Reduction)
- Where
- France
- Volunteers
- 72 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Atopic Dermatitis (AD)
Efficacy of Jelly Fig (Ficus Awkeotsang Makino) Extract for Atopic Dermatitis
The study is designed to evaluate the efficacy and safety of a topical formulation containing Ficus awkeotsang Makino extract (FAE), derived from jelly fig, in participants with mild to moderate atopic dermatitis.
- Trial name
- NCT07113366
- Testing
- FAE cream
- Where
- Taiwan
- Volunteers
- 30 people
- Sponsor
- Kaohsiung Veterans General Hospital.
Atopic Dermatitis
Study of Ruxolitinib Cream in Children With Atopic Dermatitis
This is an open-label maximum use trial to evaluate ruxolitinib safety, tolerability and blood levels after its topical application twice daily to affected areas (≥ 35% BSA) in pediatric participants with atopic dermatitis (AD)…
- Trial name
- NCT05034822
- Testing
- Ruxolitinib cream
- Where
- 15 sites in United States
- Volunteers
- 29 people
- Sponsor
- Incyte Corporation
Atopic Dermatitis
Efficacy of Topical Coal Tar in Children With Atopic Dermatitis
Rationale/hypothesis: Atopic dermatitis (AD) is an inflammatory skin disease, occurring most frequently in children. Currently, topically applied corticosteroids are used as a standard anti-inflammatory treatment.
- Trial name
- NCT03461302
- Testing
- Topical coal tar, Topical corticosteroids
- Where
- Netherlands
- Volunteers
- 80 people
- Sponsor
- Radboud University Medical Center
Dermatitis Atopic
A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis
This is a parallel group, Phase 3, multinational, multicenter, randomized, double blind, placebo-controlled, 3-arm monotherapy study for treatment of participants diagnosed with moderate to severe atopic dermatitis (AD), whose…
- Trial name
- COAST 1 (NCT06130566)
- Testing
- Amlitelimab
- Where
- 148 sites in United States, Argentina and 13 more
- Volunteers
- 601 people
- Sponsor
- Sanofi
Atopic Dermatitis (AD)
Real World Study of Oral Upadacitinib Tablets to Assess Adverse Events and Change in Disease Activity in Adolescent and Adult Chinese Participants With Atopic Dermatitis
Atopic dermatitis (AD) is a skin condition that may cause a rash and itching due to inflammation of the skin. This study will assess how safe and effective upadacitinib is in treating AD in adolescent and adult Chinese…
- Trial name
- NCT05959083
- Where
- 18 sites in China
- Volunteers
- 200 people
- Sponsor
- AbbVie
Eczema, Asthma
Influence of Probiotics on Atopy, Immunological Responses and Gut Microflora - Follow-up to 5 Years
The investigators had conducted a double-blind, randomized placebo-controlled clinical trial studying the effects of 6 months probiotics supplementation from birth on allergic disease and sensitization up to 2 years of age.
- Conditions
- Eczema, Asthma, Allergic Rhinitis
- Trial name
- NCT00365469
- Testing
- Probiotic
- Where
- Singapore
- Volunteers
- 253 people, healthy volunteers welcome
- Sponsor
- National University Hospital, Singapore
Vitiligo, Atopic Dermatitis
An Observational Study of Patients With Dermatologic Disease
TARGET-DERM+ is an observational research study to conduct a comprehensive review of outcomes for patients with dermatologic disease (DD) and providers who treat these patients.
- Conditions
- Vitiligo, Atopic Dermatitis, Alopecia Areata, Hidradenitis Suppurativa (HS)
- Trial name
- TARGET-DERM+ (NCT07748169)
- Where
- United States
- Volunteers
- 2,000,000 people
- Sponsor
- Target PharmaSolutions, Inc.
Atopic Dermatitis, Eczema
Atopic Dermatitis With Accelerometry and Polysomnography (ADAP)
The purpose of this research is to better understand how wrist-worn study devices that measure activity/motion ('accelerometry devices') can be used to assess scratching and sleep in participants aged 12-75 years, with and…
- Conditions
- Atopic Dermatitis, Eczema, Healthy
- Trial name
- ADAP (NCT05583019)
- Testing
- GENEActiv Accelerometry Device, Centrepoint Insights Watch (CPIW) Accelerometry Device, Apple Watch Accelerometry Device
- Where
- United States
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- SymmetryScience Group, Inc.
Dermatitis, Atopic
WAL 801 CL Dry Syrup in Paediatric Atopic Dermatitis Patients
Study to investigate the safety and efficacy of WAL 801 CL Dry Syrup on pruritus associated with paediatric atopic dermatitis in comparison with that of Ketotifen Fumarate Dry Syrup and to confirm the appropriateness of dosage of…
- Trial name
- NCT02182557
- Testing
- WAL 801 CL Dry Syrup, Ketotifen Fumarate Dry Syrup
- Volunteers
- 162 people
- Sponsor
- Boehringer Ingelheim